|Table of Contents|

Advances on the role of cell cycle-related genes CDKN2A,TP53,RB1 and BRCA2 in malignancies

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2018 01
Page:
153-157
Research Field:
Publishing date:

Info

Title:
Advances on the role of cell cycle-related genes CDKN2A,TP53,RB1 and BRCA2 in malignancies
Author(s):
He Xiaowei; Xu Ling
Department of Medical Oncology,the First Hospital of China Medical University,Liaoning Shenyang 110001,China.
Keywords:
cell cycle-related genes; tumor; treatment; prognosis
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2018.01.040
Abstract:
CDKN2A,TP53,RB1 and BRCA2 are cell cycle-related genes,which play an important part in the regulation of cell proliferation and apoptosis.CDKN2A,TP53,RB1 and BRCA2 genes play a vital role not only on the carcinogenesis and development of multiple tumors,but also on the treatment and prognosis of tumors.This paper reviews the progress about the effect on tumor and the influence on the curative effect and prognosis of CDKN2A,TP53,RB1 and BRCA2.

References:

［1］Wang J,Zhang XW.The gene mutation of CDKN2A and cancer［J］.Chinese Journal of Birth Health & Heredity,2007,15(7):114-116.［王静,张小为.CDKN2A基因变异与肿瘤［J］.中国优生与遗传杂志,2007,15(7):114-116.］
[2]Zeng XR,Li YY.The progress of p16INK4a in gynecology cancer［J］.China Healthcare Frontiers,2009,4(21):19-20.［曾宪瑞,李英勇.p16INK4a在妇科肿瘤中的研究进展［J］.中国医疗前沿,2009,4(21):19-20.］
[3] Jiang Y,Yan F,Liang L,et al.Meta-analysis demonstrates no association between p16INK4A promoter methylation and epithelial ovarian cancer［J］.Arch Gynecol Obstet,2017,295(3):697-704.
[4]Chang Z,Ju H,Ling J,et al.Cooperativity of oncogenic K-Ras and downregulated p16/INK4A in human pancreatic tumorigenesis［J］.PLoS One,2014,9(7):e101452.
[5]Tang B,Li Y,Qi G,et al.Clinicopathological significance of CDKN2A promoter hypermethylation frequency with pancreatic cancer ［J］.Sci Rep,2015,5:13563.
[6]Heilmann AM,Perera RM,Ecker V,et al.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers［J］.Cancer Res,2014,74(14):3947-3958.
[7]Jiang J,Gu Y,Liu J,et al.Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs［J］.Lung Cancer,2016,102:101-107.
[8]Delfaularue MH,Klapper W,Berger F,et al.High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma［J］.Blood,2015,126(5):604-611.
[9]Young RJ,Waldeck K,Martin C,et al.Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines［J］.Pigment Cell Melanoma Res,2014,27(4):590-600.
[10] Cen L,Carlson BL,Schroeder MA,et al.p16-CDK4-RB axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells［J］.Neuro Oncol,2012,14(7):870-881.
[11] Purkait S,Jha P,Sharma MC,et al.CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry［J］.Neuropathology,2013,33(4):405-412.
[12]Yue X,Zhao Y,Xu Y,et al.Mutant p53 in cancer:Accumulation,gain-of-function and therapy［J］.J Mol Biol,2017,429(11):1595-1606.
[13]Warren RS,Atreya CE,Niedzwiecki D,et al.Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer:Results of CALGB 89803［J］.Clin Cancer Res,2013,19(20):5777-5787.
[14]Zha Y,Gan P,Liu Q,et al.TP53 codon 72 polymorphism predicts efficacy of paclitaxel plus capecitabine chemotherapy in advanced gastric cancer patients［J］.Arch Med Res,2016,47(1):13-18.
[15]Kandioler D,Mittlbck M,Kappel S,et al.TP53 mutational status and prediction of benefit from adjuvant 5-fluorouracil in stage III colon cancer patients［J］.Ebiomedicine,2015,2(8):823-830.
[16]Npel-Dünnebacke S,Schulmann K,Reinacher-Schick A,et al.Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy［J］.Z Gastroenterol,2014,52(12):1394-1401.
[17]Coradini D,Biganzoli E,Ardoino I,et al.p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy［J］.Breast,2015,24(3):294-297.
[18]Kandioler D,Schoppmann SF,Zwrtek R,et al.The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes.A p53 Research Group study［J］.J Thorac Cardiovasc Surg,2014,148(5):2280-2286.
[19]Zhang M,Zhuang G,Sun X,et al.TP53 mutation-mediated genomic instability induces the evolution of chemoresistance and recurrence in epithelial ovarian cancer［J］.Diagn Pathol,2017,12(1):16.
[20]Ma X,Rousseau V,Sun H,et al.Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer［J］.Mol Oncol,2014,8(3):555-564.
[21]Liu SH,Wang SZ,Zhang H,et al.The progress of Retinoblastomal (RB1)［J］.Hereditas,2010,32(11):1097-1104.［刘双虎,王守志,张慧,等.视网膜母细胞瘤基因1(RB1)研究进展［J］.遗传,2010,32(11):1097-1104.］
[22] Indovina P,Pentimalli F,Casini N,et al.RB1 dual role in proliferation and apoptosis:Cell fate control and implications for cancer therapy［J］.Oncotarget,2015,6(20):17873-17890.
[23] Dyson NJ.RB1:A prototype tumor suppressor and an enigma［J］.Genes Dev,2016,30(13):1492-1502.
[24] Konecny GE,Winterhoff B,Kolarova T,et al.Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer［J］.Clin Cancer Res,2011,17(6):1591-1602.
[25] Geradts J,Fong KM,Zimmerman PV,et al.Correlation of abnormal RB,p16INK4A,and p53 expression with 3p loss of heterozygosity,other genetic abnormalities,and clinical features in 103 primary non-small cell lung cancers［J］.Clin Cancer Res,1999,5(4):791-800.
[26] Esuvaranathan K,Chiong E,Thamboo TP,et al.Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha［J］.Cancer,2007,109(6):1097-1105.
[27] Wooster R,Neuhausen SL,Mangion J,et al.Localization of a breast cancer susceptibility gene,BRCA2,to chromosome 13q12-13［J］.Science,1994,265(5181):2088-2090.
[28] Xia B,Sheng Q,Nakanishi K,et al.Control of BRCA2 cellular and clinical functions by a nuclear partner,PALB2［J］.Mol Cell,2006,22(6):719-729.
[29] Buisson R,Dion-Cté AM,Coulombe Y,et al.Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination［J］.Nat Struct Mol Biol,2010,17(10):1247-1254.
[30]Kobayashi H,Ohno S,Sasaki Y,et al.Hereditary breast and ovarian cancer susceptibility genes (review) ［J］.Oncol Rep,2013,30(3):1019-1029.
[31] Mehrgou A,Akouchekian M.The importance of BRCA1 and BRCA2 genes mutations in breast cancer development［J］.Med J Islam Repub Iran,2016,30:369.
[32]Harmsen MG,Hermens RP,Prins JB,et al.How medical choices influence quality of life of women carrying a BRCA mutation［J］.Crit Rev Oncol Hematol,2015,96(3):555-568.
[33] Dougherty BA,Lai Z,Hodgson DR,et al.Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting［J］.Oncotarget,2017,8(27):43653-43661.
[34] Martinez-Useros J,Garcia-Foncillas J.The role of BRCA2 mutation status as diagnostic,predictive,and prognosis biomarker for pancreatic cancer［J］.Biomed Res Int,2016,2016:1869304.
[35] Cui M,Gao XS,Gu X,et al.BRCA2 mutations should be screened early and routinely as markers of poor prognosis:Evidence from 8 988 patients with prostate cancer［J］.Oncotarget,2017,8(25):40222-40232.

Memo

Memo:
National Natural Science Foundation of China(No.81673025）；国家自然科学基金（编号：81673025）
Last Update: 2017-11-30